Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

• In July 2026, Inhibrx Biosciences entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding its credit facility to up to US$500.0 million, including an immediate US$100.0 million Term C Loan and potential Term D funding of up to US$225.0 million at the lenders' discretion.
• As part of the new debt tranche, the company issued immediately exercisable warrants to Oxford to purchase 21,457 common shares at a US$93.21 strike price, aligning lenders’ potential equity participation with Inhibrx Biosciences’ longer-term outcomes.
• We’ll now examine how this expanded US$500.0 million credit facility shapes Inhibrx Biosciences’ investment narrative, particularly around funding flexibility and optionality.

Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Inhibrx Biosciences' Investment Narrative?

To own Inhibrx Biosciences, you have to believe its emerging oncology and immunotherapy pipeline can translate strong early data into regulatory approvals and, eventually, meaningful commercial adoption, despite minimal current revenue and ongoing losses. The central short term catalysts are now tightly linked to the ozekibart BLA review in chondrosarcoma, the planned HexAgon Phase 3 start, and upcoming data updates, all of which remain intact after the recent sell off. The expanded US$500.0 million credit facility with Oxford meaningfully shifts the near term story by reducing immediate financing pressure and giving management more room to fund trials without tapping equity at current levels. That said, higher leverage, negative equity and dependence on successful trial execution remain core risks.

However, the extra debt introduces a new layer of financial risk investors should not overlook. Our valuation report unveils the possibility Inhibrx Biosciences' shares may be trading at a premium.

Exploring Other Perspectives

The single US$277.5 fair value estimate from the Simply Wall St Community sits against a wide spread of professional views, while the larger loan facility and higher leverage remind you to weigh funding flexibility against execution and balance sheet risk.

Explore another fair value estimate on Inhibrx Biosciences - why the stock might be worth just $277.50!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Inhibrx Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Inhibrx Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inhibrx Biosciences' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com